newsfilter
← Latest News
GlobeNewswire·

Otonomy Reports First Quarter 2022 Financial Results and Provides Corporate Update

Positive top-line results announced for OTO-413 Phase 2a in hearing loss; enrollment ongoing for higher dose evaluation OTO-313 Phase 2 trial in tinnitus fully enrolled with top-line results expected in August 2022; clinical safety evaluation of higher